Dr. Matulonis on the Use of Immunotherapy in Recurrent Ovarian Cancer

Dr. Matulonis on Final Data From KEYNOTE-100 in Recurrent Ovarian CancerПодробнее

Dr. Matulonis Discusses Mirvetuximab Soravtansine Plus Pembrolizumab in Ovarian CancerПодробнее

Dr. Matulonis on CPS as a Potential Biomarker in Advanced Recurrent Ovarian CancerПодробнее

Dr. Matulonis Discusses Maintenance in Ovarian CancerПодробнее

Does PCOS Increase My Cancer Risk?Подробнее

Introduction to KEYNOTE-100 trial of pembrolizumab in advanced recurrent ovarian cancerПодробнее

Dr. Matulonis Discusses Niraparib/Pembrolizumab Combo in Platinum-Resistant Ovarian CancerПодробнее

Copy of Dr. Matulonis on the Use of Immunotherapy in Recurrent Ovarian CancerПодробнее

KEYNOTE-100 update: pembrolizumab in patients with advanced recurrent ovarian cancerПодробнее

Dr. Matulonis on the Current Treatment Landscape in Ovarian CancerПодробнее

Rationale for Immunotherapy in Ovarian CancerПодробнее

Dr. Matulonis on Individualized Dosing of Niraparib in Ovarian CancerПодробнее

Dr. Ursula Matulonis on Phase III Trials Examining Cediranib Plus Olaparib in Ovarian CancerПодробнее

Role of Immunotherapy In Recurrence Management Of Ovarian Cancer.Подробнее

Dr. Eskander on Combination Approaches With Immunotherapy in Ovarian CancerПодробнее

Dr. Konstantinopoulos on Immunotherapy in Ovarian CancerПодробнее

Dr. Matulonis on the NOVA Trial of Niraparib Maintenance Therapy in Ovarian CancerПодробнее

Dr. Matulonis on Toxicities With Olaparib for Patients With Ovarian CancerПодробнее

Stanford Cancer Institute Breakthroughs in Cancer: Ursula Matulonis, MDПодробнее